| Patent Number |
Title Of Patent |
Date Issued |
| 7304043 |
.beta.-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
December 4, 2007 |
| This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2'-deoxy-.beta.-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2 |
| 6946450 |
.beta.-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
September 20, 2005 |
| This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2'-deoxy-.beta.-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2 |
| 6875751 |
3'-prodrugs of 2'-deoxy-.beta.-L-nucleosides |
April 5, 2005 |
| The present invention relates to compounds, compositions and methods for the treatment of a host infected with a hepatitis B virus. Specifically, compound and compositions of 3'-esters of 2'-deoxy-.beta.-L-nucleosides are disclosed, which can be administered either alone or in combinatio |
| 6809083 |
Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus i |
October 26, 2004 |
| Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral |
| 6787526 |
Methods of treating hepatitis delta virus infection with .beta.-L-2'-deoxy-nucleosides |
September 7, 2004 |
| A method and composition for treating a host infected with hepatitis D comprising administering an effective hepatitis D treatment amount of a described 2'-deoxy-.beta.-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof. |
| 6747149 |
Glucamine salts for treating hepatitis virus infections |
June 8, 2004 |
| N-Substituted glucamine compounds of formula I are effective in treatment of hepatitis infections, including hepatitis B and hepatitis C. In treating hepatitis infections the compounds of formular I may be used alone, or in combinatioin with another antiviral agent selected from among |
| 6602664 |
3'-azido-2',3'-dideoxyuridine in an anti-HIV effectiveness test protocol |
August 5, 2003 |
| It has been discovered that 3'-azido-2',3'-dideoxyuridine (CS-87) induces a transient mutation in HIV-1 at the 70.sup.th codon (K to R, i.e., lysine to arginine) of the reverse transcriptase region of the virus. Based on this discovery, a method and composition for treating HIV is provid |
| 6596700 |
Methods of treating hepatitis delta virus infection with .beta.-L-2'-deoxy-nucleosides |
July 22, 2003 |
| A method and composition for treating a host infected with hepatitis D comprising administering an effective hepatitis D treatment amount of a described 2'-deoxy-.beta.-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof. |
| 6569837 |
.beta.-L-2'-deoxy pyrimidine nucleosides for the treatment of hepatitis B |
May 27, 2003 |
| This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2'-deoxy-.beta.-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2 |
| 6566344 |
.beta.-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
May 20, 2003 |
| This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2'-deoxy-.beta.-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2 |
| 6545021 |
Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infec |
April 8, 2003 |
| N-Substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds of Formula I are effective in treatment of hepatitis infections, including hepatitis B and hepatitis C. In treating hepatitis infections, the compounds of Formula I may be used alone, or in combination with another antiviral agent |
| 6545007 |
Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-ox |
April 8, 2003 |
| A method for inhibiting sexual transmission of HIV comprising topically applying to the skin or epithelial tissue of a human a composition comprising a non-nucleoside reverse transcriptase inhibitor ("NNRTI") that is able to inhibit viral replication for periods exceeding 12, 24, or even |
| 6515028 |
Glucamine compounds for treating hepatitis virus infections |
February 4, 2003 |
| N-Substituted glucamine compounds of Formula I are effective in treatment of hepatitis infections, including hepatitis B and hepatitis C. In treating hepatitis infections, the compounds of Formula I may be used alone, or in combination with another antiviral agents selected from among |
| 6444652 |
.beta.-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
September 3, 2002 |
| This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2'-deoxy-.beta.-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2 |
| 6395716 |
.beta.-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
May 28, 2002 |
| This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2'-deoxy-.beta.-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2 |
| 6194391 |
3'-azido-2',3'-dideoxyuridine administration to treat HIV and related test protocol |
February 27, 2001 |
| It has been discovered that 3'-azido-2',3'-dideoxyuridine (CS-87) induces a transient mutation in HIV-1 at the 70.sup.th codon (K to R, i.e., lysine to arginine) of the reverse transcriptase region of the virus. Based on this discovery, a method and composition for treating HIV is provid |
| 6100277 |
Retroviral protease inhibitor combinations |
August 8, 2000 |
| The present invention is directed to a method for the treatment of mammalian retrovirus infections, such as HIV, using combinations of retroviral protease inhibitors which are effective in preventing the replication of the retroviruses in vitro or in vivo. This invention, in particul |
| 6069235 |
Method for carbohydrate engineering of glycoproteins |
May 30, 2000 |
| A method is disclosed for modifying the carbohydrate moiety on glycoproteins to facilitate the structural and functional analysis of said glycoproteins such as by NMR spectroscopic analysis and crystallography which comprises treating glycoprotein-secreting mammalian cells having low |
| 5622972 |
Method for treating a mammal infected with respiratory syncytial virus |
April 22, 1997 |
| A method is provided for treating a mammal infected with respiratory syncytial virus (RSV) comprising administering to the mammal an RSV inhibitory effective amount of a compound or its pharmaceutically acceptable salt of the formula ##STR1## wherein R.sup.1 is alkyl, aralkyl, ar |
